(Q34915610)

5 August 2017

title

Interleukin 17F level and interferon β response in patients with multiple sclerosis (English)

1 reference

5 August 2017

0 references

1

Hans-Peter Hartung

1 reference

5 August 2017

9

Ludwig Kappos

1 reference

5 August 2017

4

Giancarlo Comi

1 reference

5 August 2017

6

Massimo Filippi

1 reference

5 August 2017

Timon Bogumil

12

1 reference

ORCID Public Data File 2021

Douglas S Goodin

3

object named as

Douglas S Goodin

1 reference

5 August 2017

15

Rupert Sandbrink

1 reference

5 August 2017

11

Volker Knappertz

1 reference

5 August 2017

13

Susanne Schwenke

1 reference

5 August 2017

Lawrence Steinman

2

1 reference

5 August 2017

Stuart Cook

5

1 reference

5 August 2017

Paul O'Connor

7

1 reference

5 August 2017

Douglas R Jeffery

8

1 reference

5 August 2017

Robert Axtell

10

1 reference

5 August 2017

Ed Croze

14

1 reference

5 August 2017

Christopher Pohl

16

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 August 2013

1 reference

5 August 2017

1 reference

5 August 2017

volume

70

1 reference

5 August 2017

issue

8

1 reference

5 August 2017

page(s)

1017-1021

1 reference

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

Determinants of interferon β efficacy in patients with multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

Regulation of inflammatory responses by IL-17F

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

Interleukin-17 family members and inflammation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

New pieces in the puzzle: how does interferon-beta really work in multiple sclerosis?

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

Measures in the first year of therapy predict the response to interferon β in MS

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

A full genome search in multiple sclerosis

9 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4290836

Extreme discordant sib pairs for mapping quantitative trait loci in humans

9 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23732754

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ultrasensitive flow-based immunoassays using single-molecule counting

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23732754

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interferon beta in multiple sclerosis: predicting response at an early stage

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23732754

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1001/JAMANEUROL.2013.192

1 reference

5 August 2017

1 reference

5 August 2017

1 reference